Abstract
The Liver X Receptor (LXR) α and β isoforms are members of the type II nuclear receptor family which function as a heterodimer with the Retinoid X Receptor (RXR). Upon agonist binding, the formation of the LXR/RXR heterodimer takes place and ultimately the regulation of a number of genes begins. The LXR isoforms share 77% sequence homology, with LXRβ having highest expression in liver, intestine, adipose tissue, and macrophages and LXRα being ubiquitously expressed. The aim of this article is to review the reported medicinal chemistry strategies towards the optimisation of novel non-steroidal chemotypes as LXR agonists. An analysis of the structural features important for LXR ligand binding will be given, utilising both structural activity relationship data obtained from LXR assays as well as X-ray co-crystallographic data obtained with LXR ligands and the LXR ligand binding domain (LBD). The X-ray co-crystallographic data analysis will detail the key structural interactions required for LXR binding/agonist activity and reveal the differences observed between chemotype classes. It has been postulated that a LXRβ selective compound may have a beneficial outcome on the lipid profile for a ligand by dissociating the favourable and unfavourable effects of LXR agonists. Whilst there have been a few examples of compounds showing a modest level of LXRα selectivity, obtaining a potent LXRβ selective compound has been more challenging. Analysis of the SAR and X-ray cocrystallographic data suggests that the rational design of a LXRβ selective compound will not be trivial.
Keywords: Liver X Receptor (LXR), alpha (α) and beta (β) isoforms
Current Medicinal Chemistry
Title: Design, Structure Activity Relationships and X-Ray Co-Crystallography of Non-Steroidal LXR Agonists
Volume: 15 Issue: 2
Author(s): A. S. Edwards, D. J. Bennett, E. L. Carswell, A. J. Cooke and O. Nimz
Affiliation:
Keywords: Liver X Receptor (LXR), alpha (α) and beta (β) isoforms
Abstract: The Liver X Receptor (LXR) α and β isoforms are members of the type II nuclear receptor family which function as a heterodimer with the Retinoid X Receptor (RXR). Upon agonist binding, the formation of the LXR/RXR heterodimer takes place and ultimately the regulation of a number of genes begins. The LXR isoforms share 77% sequence homology, with LXRβ having highest expression in liver, intestine, adipose tissue, and macrophages and LXRα being ubiquitously expressed. The aim of this article is to review the reported medicinal chemistry strategies towards the optimisation of novel non-steroidal chemotypes as LXR agonists. An analysis of the structural features important for LXR ligand binding will be given, utilising both structural activity relationship data obtained from LXR assays as well as X-ray co-crystallographic data obtained with LXR ligands and the LXR ligand binding domain (LBD). The X-ray co-crystallographic data analysis will detail the key structural interactions required for LXR binding/agonist activity and reveal the differences observed between chemotype classes. It has been postulated that a LXRβ selective compound may have a beneficial outcome on the lipid profile for a ligand by dissociating the favourable and unfavourable effects of LXR agonists. Whilst there have been a few examples of compounds showing a modest level of LXRα selectivity, obtaining a potent LXRβ selective compound has been more challenging. Analysis of the SAR and X-ray cocrystallographic data suggests that the rational design of a LXRβ selective compound will not be trivial.
Export Options
About this article
Cite this article as:
Edwards S. A., Bennett J. D., Carswell L. E., Cooke J. A. and Nimz O., Design, Structure Activity Relationships and X-Ray Co-Crystallography of Non-Steroidal LXR Agonists, Current Medicinal Chemistry 2008; 15 (2) . https://dx.doi.org/10.2174/092986708783330584
DOI https://dx.doi.org/10.2174/092986708783330584 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Antioxidants to Mitochondria: A Potential New Therapeutic Strategy for Cardiovascular Diseases
Current Pharmaceutical Design Atypical antipsychotics and inverse agonism at 5-HT<sub>2</sub> receptors
Current Pharmaceutical Design Biomarkers of Cell Damage Induced by Oxidative Stress in Parkinsons Disease and Related Models
Central Nervous System Agents in Medicinal Chemistry Graphene and Graphene Oxide as Super Materials
Current Inorganic Chemistry (Discontinued) Angiogenesis and Metastasis Inhibitors for the Treatment of Malignant Melanoma
Mini-Reviews in Medicinal Chemistry The Role of Neurophysiological Biomarkers in Obsessive-Compulsive Disorder
Current Medicinal Chemistry Peptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugs
Current Medicinal Chemistry State of the Art in Medical and Surgical Management of Pneumothorax
Current Respiratory Medicine Reviews Advances in Studies on Neurodegenerative Diseases and their Treatments
Current Topics in Medicinal Chemistry Formulation Studies on Novel Self-Solidifying Self-Nanoemulsifying Drug Delivery Systems of Nebivolol Hydrochloride
Pharmaceutical Nanotechnology Molecular Chaperone Disorders: Defective Hsp60 in Neurodegeneration
Current Topics in Medicinal Chemistry Mucoadhesive Buccal Systems as a Novel Strategy for Anti-Inflammatory Drugs Administration
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Gender Differences in Pharmacokinetics and Side Effects of Second Generation Antipsychotic Drugs
Current Neuropharmacology Molecular Strategies for the Treatment of Huntingtons Disease
Current Pharmacogenomics Human Platelets Express Authentic CB1 and CB2 Receptors
Current Neurovascular Research Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Psychological Perspectives of Inflammatory Bowel Disease Patients Undergoing Surgery: Rightful Concerns and Preconceptions
Current Drug Targets Endocannabinoid System: A Multi-Facet Therapeutic Target
Current Clinical Pharmacology The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Ligand Docking and Structure-based Virtual Screening in Drug Discovery
Current Topics in Medicinal Chemistry